Biosino Bio-Technology and Science Inc
HKEX:8247
P/FCFE
Price to FCFE
Price to Free Cash Flow To Equity (P/FCFE) ratio is a valuation multiple that compares a company’s market capitalization to the amount of free cash flow available for equity shareholders. This metric is very similar to the P/OCF but is considered a more exact measure, owing to the fact that it uses free cash flow, which subtracts capital expenditures (CapEx) from a company's operating cash flow.
Market Cap | P/FCFE | ||||
---|---|---|---|---|---|
CN |
B
|
Biosino Bio-Technology and Science Inc
HKEX:8247
|
123m HKD | -3.8 | |
US |
Abbvie Inc
NYSE:ABBV
|
281.6B USD | 8.3 | ||
US |
Amgen Inc
NASDAQ:AMGN
|
165.6B USD | 17.1 | ||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
116.2B USD | 34.5 | ||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
108.7B USD | 27.8 | ||
AU |
CSL Ltd
ASX:CSL
|
136.2B AUD | 184.2 | ||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
83.7B USD | 10.5 | ||
US |
Moderna Inc
NASDAQ:MRNA
|
62.3B USD | -16 | ||
US |
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | -61.5 | ||
US |
Biogen Inc
NASDAQ:BIIB
|
31.9B USD | 29.8 | ||
KR |
Celltrion Inc
KRX:068270
|
38T KRW | -459 |
P/FCFE Forward Multiples
Forward P/FCFE multiple is a version of the P/FCFE ratio that uses forecasted free cash flow to equity for the P/FCFE calculation. 1-Year, 2-Years, and 3-Years forwards use free cash flow to equity forecasts for 1, 2, and 3 years ahead, respectively.